These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35392962)

  • 1. Health utilities and costs for neuromyelitis optica spectrum disorder.
    Hughes DA; Bourke S; Jones A; Bhatt R; Huda S; Mutch K; Jacob A
    Orphanet J Rare Dis; 2022 Apr; 17(1):159. PubMed ID: 35392962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying the relationship between disability progression and quality of life in patients treated for NMOSD: Insights from the SAkura studies.
    Levy M; Haycox AR; Becker U; Costantino C; Damonte E; Klingelschmitt G; von Büdingen HC; Wallenstein G; Maio DD; Szczechowski L
    Mult Scler Relat Disord; 2022 Jan; 57():103332. PubMed ID: 35158426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCE
    Hümmert MW; Schöppe LM; Bellmann-Strobl J; Siebert N; Paul F; Duchow A; Pellkofer H; Kümpfel T; Havla J; Jarius S; Wildemann B; Berthele A; Bergh FT; Pawlitzki M; Klotz L; Kleiter I; Stangel M; Gingele S; Weber MS; Faiss JH; Pul R; Walter A; Zettl UK; Senel M; Stellmann JP; Häußler V; Hellwig K; Ayzenberg I; Aktas O; Ringelstein M; Schreiber-Katz O; Trebst C;
    Neurology; 2022 Mar; 98(11):e1184-e1196. PubMed ID: 35082170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life of patients with multiple sclerosis and neuromyelitis optica spectrum disorders: Cross-sectional and longitudinal analysis.
    Kim S; Lee EJ; Kim KW; Seo D; Moon S; Kim KK; Lim YM
    Mult Scler Relat Disord; 2022 Feb; 58():103500. PubMed ID: 35032884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health utilities of patients with multiple sclerosis and neuromyelitis optica spectrum disorders in Thailand.
    Siritho S; Thavorncharoensap M; Chanatittarat C; Pasogpakdee P; Apiwattanakul M; Prayoonwiwat N; Chankrachang S; Riewpaiboon A; Chaikledkaew U
    Mult Scler Relat Disord; 2018 Aug; 24():151-156. PubMed ID: 30015079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand.
    Claflin S; Campbell JA; Norman R; Mason DF; Kalincik T; Simpson-Yap S; Butzkueven H; Carroll WM; Palmer AJ; Blizzard CL; van der Mei I; Henson GJ; Taylor BV
    Eur J Health Econ; 2023 Aug; 24(6):939-950. PubMed ID: 36149605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Utilities and Costs for Motor Neurone Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2019 Nov; 22(11):1257-1265. PubMed ID: 31708062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F; Devlin N; Luo N
    Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Patients with Neuromyelitis Optica Spectrum Disorder Using the EQ-5D.
    Mealy MA; Boscoe A; Caro J; Levy M
    Int J MS Care; 2019; 21(3):129-134. PubMed ID: 31191178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.
    Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
    Patient; 2019 Aug; 12(4):383-392. PubMed ID: 30607809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.
    Meregaglia M; Borsoi L; Cairns J; Tarricone R
    Eur J Health Econ; 2019 Mar; 20(2):181-193. PubMed ID: 28948436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis.
    Pickard AS; Gooderham M; Hartz S; Nicolay C
    J Med Econ; 2017 Jan; 20(1):19-27. PubMed ID: 27471948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysphagia in neuromyelitis optica spectrum disorder and multiple sclerosis: A comparison of frequency, severity, and effects on quality of life.
    Afsharzadeh M; Mirmosayyeb O; Vaheb S; Shaygannejad A; Maracy M; Shaygannejad V
    Mult Scler Relat Disord; 2024 Jul; 87():105640. PubMed ID: 38692153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial.
    Xie J; Wang Y; Xu Y; Fine JT; Lam J; Garrison LP
    J Med Econ; 2022; 25(1):51-58. PubMed ID: 34907813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.
    Hümmert MW; Bütow F; Tkachenko D; Ayzenberg I; Pakeerathan T; Hellwig K; Klotz L; Häußler V; Stellmann JP; Warnke C; Goereci Y; Etgen T; Luessi F; Bronzlik P; Gingele S; Lauenstein AS; Kleiter I; Rommer PS; Paul F; Bellmann-Strobl J; Duchow A; Then Bergh F; Pul R; Walter A; Pellkofer H; Kümpfel T; Pompsch M; Kraemer M; Albrecht P; Aktas O; Ringelstein M; Senel M; Giglhuber K; Berthele A; Jarius S; Wildemann B; Trebst C;
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36693760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Direct Comparison of the Measurement Properties of EQ-5D-5L, PROMIS-29+2 and PROMIS Global Health Instruments and EQ-5D-5L and PROPr Utilities in a General Population Sample.
    Rencz F; Brodszky V; Janssen MF
    Value Health; 2023 Jul; 26(7):1045-1056. PubMed ID: 36804583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-Related Quality of Life of Patients with HIV/AIDS in Bogotá, Colombia.
    Keaei M; Kuhlmann J; Conde R; Evers SM; Gonzalez J; Govers M; Hiligsmann M
    Value Health Reg Issues; 2016 Dec; 11():68-72. PubMed ID: 27986201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
    Cheung PWH; Wong CKH; Cheung JPY
    Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
    Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
    J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.